Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma

Oncology

Volumn 69, Issue 5, 2005, Pages 363-371

  Eckel, F ^a   Von Delius, S ^a   Mayr, M ^a   Dobritz, M ^a   Fend, F ^a   Hosius, C ^b   Schleyer, E ^c   Schulte Frohlinde, E ^a   Schmid, R M ^a   Lersch, C ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Novartis   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

c kit; Hepatocellular carcinoma; Imatinib; Phase II clinical trials; Platelet derived growth factor receptor

Indexed keywords

BILIRUBIN; CREATININE; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ACUTE HEART INFARCTION; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASCITES; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOVASCULAR DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; IMMUNOHISTOCHEMISTRY; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MALE; MUSCLE CRAMP; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT FAILURE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; FIBROSIS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; STEM CELLS; TIME FACTORS; TREATMENT OUTCOME;

EID: 29144474459     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089990     Document Type: Article

References (32)

1. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817-823.
2. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
3. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003;362:1907-1917.
4. Carr BI: Hepatocellular carcinoma: current management and future trends. Gastroenterology 2004;127:S218-S224.
5. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442.
6. Ostman A: PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004;15:275-286.
7. Tsou AP, Wu KM, Tsen TY, Chi CW, Chiu JH, Lui WY, Hu CP, Chang C, Chou CK, Tsai SF: Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics 1998;50:331-340.
8. Fang CH, Gong JQ, Zhang W: Function of oval cells in hepatocellular carcinoma in rats. World J Gastroenterol 2004;10:2482-2487.
9. Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner AM, Weiskirchen R: Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest 2004;84:766-777.
10. Heldin CH, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-1316.
11. Savage DG, Antman KH: Imatinib mesylate - a new oral targeted therapy. N Engl J Med 2002;346:683-693.
12. Ramadori G, Fuzesi L, Grabbe E, Pieler T, Armbrust T: Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis. Anticancer Drugs 2004;15:405-409.
13. Schleyer E, Pursche S, Kohne CH, Schuler U, Renner U, Gschaidmeier H, Freiberg-Richter J, Leopold T, Jenke A, Bonin M, Bergemann T, le Coutre P, Gruner M, Bornhauser M, Ottmann OG, Ehninger G: Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. J Chromatogr B Analyt Technol Biomed Life Sci 2004;799:23-36.
14. le Coutre P, Kreuzer KA, Pursche S, Bonin M, Leopold T, Baskaynak G, Dorken B, Ehninger G, Ottmann O, Jenke A, Bornhauser M, Schleyer E: Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2004;53:313-323.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
16. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-151.
17. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-755.
18. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sola R, Rodes J, Bruix J: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-1739.
19. Farinati F, Rinaldi M, Gianni S, Naccarato R: How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system. Cancer 2000;89:2266-2273.
20. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-1432.
21. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
22. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R, Judson I: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-1134.
23. Chung CY, Yeh KT, Hsu NC, Chang JH, Lin JT, Horng HC, Chang CS: Expression of c-kit protooncogene in human hepatocellular carcinoma. Cancer Lett 2005;217:231-236.
24. Potti A, Ganti AK, Tendulkar K, Chitajallu S, Sholes K, Koch M, Kargas S: HER-2/neu and CD117 (C-kit) overexpression in hepatocellular and pancreatic carcinoma. Anticancer Res 2003;23:2671-2674.
25. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, Sauter G: Prevalence of KIT expression in human tumors. J Clin Oncol 2004;22:4514-4522.
26. Sun HC, Tang ZY: Angiogenesis in hepatocellular carcinoma: The retrospectives and perspectives. J Cancer Res Clin Oncol 2004;130:307-319.
27. Wang SY, Chen B, Zhan YQ, Xu WX, Li CY, Yang RF, Zheng H, Yue PB, Larsen SH, Sun HB, Yang X: SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells. J Hepatol 2004;41:267-273.
28. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;8:935-942.
29. Ramanathan RK, Remick SC, Mulkerin D, Takimoto C, Doroshow JH, Hamilton A, Lorusso P, Ivy P, Murgo A, Peng B: P-5331: a phase I pharmacokinetic (PK) study of STI571 in patients (pts) with advanced malignancies and varying degrees of liver dysfunction (LD) (abstract 502). Proc Am Soc Clin Oncol 2003;22:126.
30. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, Capdeville R: Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004;22:935-942.
31. Gines P, Cardenas A, Arroyo V, Rodes J: Management of cirrhosis and ascites. N Engl J Med 2004;350:1646-1654.
32. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.